Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.59 |
| ▸ | PPARA | Q07869 | 5/20 | 0.59 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5513320 | 0.93 | PPARD (0.52) | PPARDPPARAPPARGCYP1A2CYP2C9 | |
| SCHEMBL5509580 | 0.90 | PPARD (0.68) | PPARDPPARAMAOBPPARGFFAR1 | |
| SCHEMBL5508838 | 0.89 | PPARD (0.62) | PPARDPPARAMAOBPPARGCYP1A2 | |
| SCHEMBL5512616 | 0.84 | PPARD (0.84) | PPARDPPARAMAOBPPARGPTGDR | |
| SCHEMBL5511262 | 0.83 | PPARD (0.64) | PPARDPPARAMAOBPPARGNPC1 | |
| SCHEMBL5510036 | 0.83 | PPARD (0.64) | PPARDPPARAPPARG | |
| SCHEMBL5508806 | 0.82 | PPARD (0.66) | PPARDPPARAPPARGCYP1A2FFAR1 | |
| SCHEMBL5505908 | 0.81 | PPARD (0.64) | PPARDPPARAMAOBPPARGNPC1 | |
| SCHEMBL5520221 | 0.81 | PPARD (0.55) | PPARDPPARAMAOBPPARG | |
| SCHEMBL5512164 | 0.81 | PPARD (0.53) | PPARDPPARAPPARGMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-RE39916-E1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER LAMBERT COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-6964983-B2 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY, LLC (US) | 2005-11-15 | — | — | US | disclosed |
| US-6939875-B2 | Carbocyclic oxy sulfides such as [4-(Biphenyl-4-ylmethylsulfanyl)-5-methoxy-2-methyl-phenoxy]-acetic acid, used to control peroxisome proliferator activated receptors (PPAR), for prophylaxis of metabolic disorders | WARNER-LAMBERT COMPANY (US) | 2005-09-06 | — | — | US | disclosed |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | AUERBACH BRUCE J (US) | 2005-07-14 | — | — | US | disclosed |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | AUERBACH BRUCE J (US) | 2005-05-26 | — | — | US | disclosed |
| EP-1494989-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2005-01-12 | — | — | EP | disclosed |
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | WARNER-LAMBERT COMPANY | 2003-12-04 | — | — | US | disclosed |
| WO-2003084916-A2 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225158-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885MAOB 3512/4885 |
| US-20050113440-A1 | Compounds that modulate PPAR activity and methods for their preparation | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885MAOB 3512/4885 |
| US-20050153996-A1 | COMPOUNDS THAT MODULATE PPAR ACTIVITY AND METHODS FOR THEIR PREPARATION | GPR119, PPARA, PPARG | PPARD 4/4885PPARA 2/4885MAOB 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.